^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TNFα inhibitor

    Related drugs:
    1d
    Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma (clinicaltrials.gov)
    P1/2, N=100, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Entyvio (vedolizumab)
    3d
    TIMPANI: Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis (clinicaltrials.gov)
    P2, N=130, Recruiting, ANRS, Emerging Infectious Diseases | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    3d
    WAVE T1D: A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2026 --> Dec 2025
    Trial initiation date
    4d
    Neuropilin-2 (NRP2) mediates sorafenib resistance in clear cell renal cell carcinoma via the NRP2/NF-κB/TNFα axis. (PubMed, Am J Cancer Res)
    These effects are mediated through the NRP2/NF-κB/TNFα axis, which also underlies NRP2-induced sorafenib resistance. Targeting this axis with the TNF-α inhibitor adalimumab effectively reversed sorafenib resistance in ccRCC, suggesting a promising therapeutic strategy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    sorafenib
    7d
    Preventive and therapeutic effects of co-administration of Bacteroides thetaiotaomicron and infliximab on dextran sodium sulfate-induced colitis in mice. (PubMed, Intest Res)
    This combination also exhibited synergistic improvement in colitis severity in treated mice. These findings underscore the therapeutic potential of B. thetaiotaomicron in IBD, either alone or in combination with infliximab, and support further development of microbiota-based strategies for IBD prevention and treatment.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MUC2 (Mucin 2) • TFF3 (Trefoil factor 3) • OCLN (Occludin)
    7d
    Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year. (PubMed, Dermatol Ther (Heidelb))
    Bimekizumab treatment resulted in consistent, sustained efficacy to 52 weeks in biologic-naïve and TNFi-IR individuals with PsA and baseline plaque-type psoriasis and nail involvement. Bimekizumab was well tolerated, with a safety profile consistent with previous reports. Graphical abstract available for this article.
    Journal
    |
    IL17A (Interleukin 17A)
    7d
    Efficacy of ozoralizumab in rheumatoid arthritis patients with large joint involvement: a post hoc analysis of OHZORA and NATSUZORA trials. (PubMed, RMD Open)
    Ozoralizumab has the potential to improve disease activity and physical dysfunction and prevent joint destruction in patients, regardless of the presence of LJI, and is a reasonable treatment option, even for patients with LJI.
    Clinical • Retrospective data • Journal
    |
    IL6 (Interleukin 6)
    |
    methotrexate
    8d
    ZEST: Zymfentra (Infliximab-dyyb) REal World Cohort STudy (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, University of North Carolina, Chapel Hill | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    8d
    Lenalidomide for Adult Histiocyte Disorders (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2025 --> Feb 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    lenalidomide
    10d
    Influence of anti-tumor necrosis factor (TNF) treatments on T cell cytokine production in patients with inflammatory joint diseases - comparison of etanercept and anti-TNF monoclonal antibodies. A double-blind, prospective, placebo-controlled study. (PubMed, J Physiol Pharmacol)
    In summary, we ascertain that treatment with TNF inhibitors does not affect Th1, Th2, or Th17 responses. Etanercept and monoclonal antibodies differ in their effect on IL-17A+DN T cells.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IL17A (Interleukin 17A) • IL4 (Interleukin 4)
    10d
    Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study. (PubMed, Eur J Gastroenterol Hepatol)
    One quarter of IBD patients requiring intensified anti-TNFa therapie were successfully deescalated to standard dosing, after a median of 16.0 (IQR: 8.0-36.0) months.
    Journal • Real-world evidence
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Simponi (golimumab)
    13d
    BOOSTERS: Biologics in Folliculitis Decalvans : an Adaptative Trial Research (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New P2 trial